Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.

MLA

Park, Soo Jin, et al. “Efficacy and Safety of Intravenous Administration of High-Dose Selenium for Preventing Chemotherapy-Induced Peripheral Neuropathy in Platinum-Sensitive Recurrent Ovarian, Fallopian or Primary Peritoneal Cancer: Study Protocol for a Phase III, Double-Blind, Randomized Study.” Journal of Gynecologic Oncology, vol. 32, no. 5, Sept. 2021, p. e73. EBSCOhost, https://doi.org/10.3802/jgo.2021.32.e73.

APA

Park, S. J., Yim, G. W., Paik, H., Lee, N., Lee, S., Lee, M., & Kim, H. S. (2021). Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study. Journal of Gynecologic Oncology, 32(5), e73. https://doi.org/10.3802/jgo.2021.32.e73

Chicago

Park, Soo Jin, Ga Won Yim, Haerin Paik, Nara Lee, Seungmee Lee, Maria Lee, and Hee Seung Kim. 2021. “Efficacy and Safety of Intravenous Administration of High-Dose Selenium for Preventing Chemotherapy-Induced Peripheral Neuropathy in Platinum-Sensitive Recurrent Ovarian, Fallopian or Primary Peritoneal Cancer: Study Protocol for a Phase III, Double-Blind, Randomized Study.” Journal of Gynecologic Oncology 32 (5): e73. doi:10.3802/jgo.2021.32.e73.